Quantification of the forgiveness of drugs to imperfect adherence

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 3, 2015, Pages 204-211

  Assawasuwannakit, P ^a   Braund, R ^a   Duffull, S B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; WARFARIN;

ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG HALF LIFE; EC50; MATHEMATICAL PHENOMENA; MAXIMUM EFFECT; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; VOLUME OF DISTRIBUTION;

EID: 84936742746     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.4     Document Type: Article

References (29)

1. DiMatteo, M.R., Giordani, P.J., Lepper, H.S., &, Croghan, T.W., Patient adherence and medical treatment outcomes a meta-analysis. Med. Care 40, 794-811 (2002).
2. Simpson, S.H., et al,. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333, 15 (2006).
3. Vrijens, B., et al,. A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol. 73, 691-705 (2012).
4. World Health Organization. Adherence to Long-term Therapies: Evidence for Action (Geneva: WHO, 2003).
5. Urquhart, J., Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv. Drug Deliv. Rev. 33, 207-219 (1998).
6. Urquhart, J., The electronic medication event monitor. Lessons for pharmacotherapy. Clin. Pharmacokinet. 32, 345-356 (1997).
7. Osterberg, L.G., Urquhart, J., &, Blaschke, T.F., Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin. Pharmacol. Ther. 88, 457-459 (2010).
8. Blaschke, T.F., Osterberg, L., Vrijens, B., &, Urquhart, J., Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52, 275-301 (2012).
9. Hughes, D.A., &, Walley, T., Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. Clin. Pharmacol. Ther. 74, 1-8 (2003).
10. Shuter, J., Sarlo, J.A., Kanmaz, T.J., Rode, R.A., &, Zingman, B.S., HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J. Acquir. Immune Defic. Syndr. 45, 4-8 (2007).
11. Dickinson, L., et al,. Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J. Antimicrob. Chemother. 62, 161-167 (2008).
12. Schwalbe, O., Scheerans, C., Freiberg, I., Schmidt-Pokrzywniak, A., Stang, A., &, Kloft, C., Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals. BMC Health Serv. Res. 10, 232 (2010).
13. Lowy, A., et al,. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int. J. Clin. Pract. 65, 41-53 (2011).
14. Srivastava, S., Pasipanodya, J.G., Meek, C., Leff, R., &, Gumbo, T., Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 204, 1951-1959 (2011).
15. Rode, R., Vrijens, B., Niemi, K., Wikstrom, K., Heuser, R., &, Podsadecki, T., Differences in treatment compliance between lopinavir/ritonavir (LPV/r) given once (QD) versus twice (BID) daily do not affect virologic or immunologic outcomes. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16-19 December 2005.
16. Burnier, M., Brede, Y., &, Lowy, A., Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int. J. Clin. Pract. 65, 127-133 (2011).
17. Boissel, J.P., &, Nony, P., Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin. Pharmacokinet. 41, 1-6 (2002).
18. Nony, P., &, Boissel, J.P., Use of sensitivity functions to characterise and compare the forgiveness of drugs. Clin. Pharmacokinet. 41, 371-380 (2002).
19. Gohore, D.G., Fenneteau, F., Barrière, O., Li, J., &, Nekka, F., Rational drug delineation: a global sensitivity approach based on therapeutic tolerability to deviations in execution. Pharmacol. Pharm. 1, 42-52 (2010).
20. Comte, L., Vrijens, B., Tousset, E., Gerard, P., &, Urquhart, J., Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J. Pharmacokinet. Pharmacodyn. 34, 549-558 (2007).
21. Vrijens, B., Claeys, M.J., Legrand, V., Vandendriessche, E., &, Van de Werf, F., Projected inhibition of platelet aggregation with ticagrelor BID versus clopidogrel QD based on patient adherence data (the TWICE project). Br. J. Clin. Pharmacol. 77, 746-755 (2013).
22. Girard, P., Blaschke, T.F., Kastrissios, H., &, Sheiner, L.B., A Markov mixed effect regression model for drug compliance. Stat. Med. 17, 2313-2333 (1998).
23. Ribbing, J., &, Jonsson, E.N., Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J. Pharmacokinet. Pharmacodyn. 31, 109-134 (2004).
24. Lagishetty, C.V., Coulter, C.V., &, Duffull, S.B., Design of pharmacokinetic studies for latent covariates. J. Pharmacokinet. Pharmacodyn. 39, 87-97 (2012).
25. Wang, W., Husan, F., &, Chow, S.C., The impact of patient compliance on drug concentration profile in multiple doses. Stat. Med. 15, 659-669 (1996).
26. Wong, D., Modi, R., &, Ramanathan, M., Assessment of Markov-dependent stochastic models for drug administration compliance. Clin. Pharmacokinet. 42, 193-204 (2003).
27. Blesius, A., Chabaud, S., Cucherat, M., Mismetti, P., Boissel, J.P., &, Nony, P., Compliance-guided therapy: a new insight into the potential role of clinical pharmacologists. Clin. Pharmacokinet. 45, 95-104 (2006).
28. Hamberg, A.K., et al,. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin. Pharmacol. Ther. 87, 727-734 (2010).
29. Wright, D.F., &, Duffull, S.B., A Bayesian dose-individualization method for warfarin. Clin. Pharmacokinet. 52, 59-68 (2013).